Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP and Chief Legal Officer | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,131 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 828 · Balance 19,131 F1: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 828 | $502.71 | $416,243.88 |
DisclosureSEC source: 0000875320-26-000241 · wk-form4_1783368787.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,131 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 828 | $439.91 | $364,245.48 |
DisclosureSEC source: 0000875320-26-000230 · wk-form4_1780517191.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,959 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,104 | $425.02 | $469,222.08 |
DisclosureSEC source: 0000875320-26-000183 · wk-form4_1778015480.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,729 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 978 | $449.17 | $439,288.26 |
DisclosureSEC source: 0000875320-26-000157 · wk-form4_1775249628.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,833 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 892 | $495.96 | $442,396.32 |
DisclosureSEC source: 0000875320-26-000134 · wk-form4_1772659274.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,811 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $305.57 | $91,671.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 6 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $305.57 (range $305.55 to $305.58). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,743 | $305.01 | $531,632.43 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,905 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $305.01 (range $304.54 to $305.53). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $303.99 | $212,793.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,648 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $303.99 (range $303.48 to $304.46). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $302.35 | $30,235.00 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 698 | $301.63 | $210,537.74 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,448 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.63 (range $301.23 to $302.01). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 206 | $300.26 | $61,853.56 |
DisclosureSEC source: 0000899243-22-029023 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,146 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.26 (range $300.00 to $300.28). Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 36 | $300.32 | $10,811.52 |
DisclosureSEC source: 0000899243-22-028470 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,352 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 946 | $300.00 | $283,800.00 |
DisclosureSEC source: 0000899243-22-028249 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,388 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 35 | $254.36 | $8,902.60 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,334 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $254.36 (range $254.15 to $254.57). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 34 | $253.87 | $8,631.58 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,369 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $253.87 (range $253.14 to $254.13). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $252.49 | $5,049.80 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,403 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $252.49 (range $252.12 to $253.11). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19 | $251.57 | $4,779.83 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,423 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $251.57 (range $251.05 to $251.81). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 25 | $250.77 | $6,269.25 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,442 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $250.77 (range $250.00 to $250.90). Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $278.04 | $2,780.40 |
DisclosureSEC source: 0000899243-22-016320 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,334 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22 | $276.72 | $6,087.84 |
DisclosureSEC source: 0000899243-22-016320 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,344 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $276.72 (range $276.31 to $277.06). Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30 | $275.62 | $8,268.60 |
DisclosureSEC source: 0000899243-22-016320 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,366 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $275.62 (range $275.22 to $276.19). Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 41 | $274.75 | $11,264.75 |
DisclosureSEC source: 0000899243-22-016320 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,396 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $274.74 (range $274.20 to $275.14). Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17 | $273.37 | $4,647.29 |
DisclosureSEC source: 0000899243-22-016320 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,437 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $273.37 (range $273.13 to $273.87). Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,554 | $227.86 | $354,094.44 |
DisclosureSEC source: 0000899243-22-008120 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,454 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 712 | $232.51 | $165,547.12 |
DisclosureSEC source: 0000899243-22-007213 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,008 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 474 | $237.74 | $112,688.76 |
DisclosureSEC source: 0001209191-22-009238 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,720 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,194 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,987 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,353 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 47 | $216.88 | $10,193.36 |
DisclosureSEC source: 0001209191-21-033986 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,253 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.34). F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.88 (range $216.43 to $217.21). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 65 | $215.95 | $14,036.75 |
DisclosureSEC source: 0001209191-21-033986 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.34). F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 256 | $212.28 | $54,343.68 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 6 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,253 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $212.28 (range $212.08 to $212.45). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,460 | $211.67 | $309,038.20 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,509 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $211.67 (range $211.08 to $212.07). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 844 | $210.64 | $177,780.16 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,969 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $210.64 (range $210.00 to $210.97). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 111 | $209.37 | $23,240.07 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,813 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $209.37 (range $208.98 to $209.64). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,119 | $208.39 | $233,188.41 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,924 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $208.39 (range $207.93 to $208.67). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,351 | $207.57 | $280,427.07 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,043 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $207.57 (range $206.93 to $207.92). F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.